# US 2013/0210681 A1 · Direct Cloning

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0210681 A1
- Document ID: US20130210681A1
- Status: Published application
- Kind: A1
- Application number: 13/806,086
- Filed: 2011-06-10
- Published: 2013-08-15
- Earliest claimed: 2010-06-10
- Assignees: Gene Bridges GMBH
- Inventors: Youming Zhang; Jun Fu; Adrian Francis Stewart
- Web page: https://patentgrep.com/patent/US20130210681A1

## CPC

- C12N 15/1096: {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 15/10: Processes for the isolation, preparation or purification of DNA or RNA (chemical preparation of DNA or RNA C07H21/00; preparation of non-structural polynucleotides from microorganisms or with enzymes C12P19/34)
- C12N 15/1093: {General methods of preparing gene libraries, not provided for in other subgroups}
- C12N 15/902: {using homologous recombination}
- C12Y 301/16: Exonucleases active with either ribo- or deoxyribonucleic acids and producing 3'-phosphomonoesters (3.16)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A method for performing homologous recombination between at least a first nucleic acid molecule and a second nucleic acid molecule which share at least one region of sequence homology. A method for improving the efficiency of homologous recombination.

## Claims

### Claim 1

A method for performing homologous recombination between at least a first nucleic acid molecule and a second nucleic acid molecule which share at least one region of sequence homology, wherein the method comprises bringing the first nucleic acid molecule into contact with the second nucleic acid molecule in the presence of a 5′ to 3′ exonuclease and an annealing protein;
wherein the 5′ to 3′ exonuclease comprises a region having 5′ to 3′ exonuclease activity and at least:
i) amino acids 564-587 of SEQ ID NO:1; or
ii) a 24 amino acid sequence having at least 70% identity to amino acids 564-587 of SEQ ID NO:1 over the entire length of the 24 amino acid sequence.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the 5′ to 3′ exonuclease is RecE.

### Claim 3 (depends on 1, 2)

A method according to claim 1 or claim 2, wherein the RecE comprises or consists of amino acids 564-866 of SEQ ID NO:1 or a variant thereof comprising or consisting of a sequence 303 amino acids in length that has at least 70% sequence identity to SEQ ID NO:1 over the entire length of the 303 amino acid sequence.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1 to 3, wherein the RecE comprises or consists of a sequence selected from the group consisting of amino acids 1-866, 141-866, 423-866 or 564-866 of SEQ ID NO:1 or a variant of a sequence from this group, wherein the variant has at least 70% sequence identity to SEQ ID NO:1 over the entire length of the sequence.

### Claim 5

The method of any one of the preceding claims, wherein the RecE has at least 75%, 80%, 85%, 90%, 95%, 98% or 99% sequence identity to the RecE provided in SEQ ID NO:1.

### Claim 6

The method of any one of the preceding claims, wherein the RecE is full-length RecE.

### Claim 7 (depends on 2, 3, 4, 5, 6)

The method of any one of claims 2 to 6, wherein the annealing protein is RecT.

### Claim 8

The method of any one of the preceding claims wherein the first and second nucleic acid molecules are linear nucleic acid molecules.

### Claim 9

The method of any one of the preceding claims wherein the homologous recombination is carried out in a host cell.

### Claim 10 (depends on 9)

The method of claim 9 wherein the 5′ to 3′ exonuclease is expressed from heterologous DNA.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The method of any one of claims 1-9 wherein the 5′ to 3′ exonuclease is RecE and is expressed from the RecE gene of an integrated prophage, and wherein expression of RecE is driven by a heterologous promoter.

### Claim 12 (depends on 10, 11)

The method of claim 10 or claim 11, wherein expression of the 5′ to 3′ exonuclease is driven by an inducible promoter such as an arabinose inducible promoter or a rhamnose inducible promoter.

### Claim 13

The method of any one of the preceding claims, wherein the second nucleic acid is a linearised cloning vector, such as a linearised BAC, a linearised p15A origin based vector, a linearised pBR322 origin based vector, a linearised fosmid, a linearised pUC origin based vector or a linearised ColE1 origin based vector.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1 to 12, wherein the first and second nucleic acid molecules are linear and the method further comprises bringing a third nucleic acid molecule into contact with the first and second nucleic acid molecules in the presence of the 5′ to 3′ exonuclease and the annealing protein, wherein the first nucleic acid molecule shares a region of homology with the second nucleic acid molecule and shares a different region of homology with the third nucleic acid molecule, wherein the second nucleic acid molecule shares a region of homology with the first nucleic acid molecule and shares a different region of homology with the third nucleic acid molecule and wherein the third nucleic acid molecule shares a region of homology with the second nucleic acid molecule and shares a different region of homology with the first nucleic acid molecule.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The method of any one of claims 1 to 12, wherein first and second nucleic acid molecules are linear and the method further comprises bringing a third nucleic acid molecule and a fourth nucleic acid molecule into contact with the first and second nucleic acid molecules in the presence of the 5′ to 3′ exonuclease and the phage annealing protein, wherein the wherein the first nucleic acid molecule shares a region of homology with the second nucleic acid molecule and shares a different region of homology with the fourth nucleic acid molecule, wherein the second nucleic acid molecule shares a region of homology with the first nucleic acid molecule and shares a different region of homology with the third nucleic acid the second nucleic acid molecule and shares a different region of homology with the fourth nucleic acid molecule, and wherein the fourth nucleic acid molecule shares a region of homology with the third nucleic acid molecule and shares a different region of homology with the first nucleic acid molecule.

### Claim 16 (depends on 15)

The method of claim 15, wherein the first nucleic acid molecule comprises a sequence of interest, the second and fourth nucleic acid molecules are short oligonucleotides and the third nucleic acid molecule is a cloning vector.

### Claim 17

The method of any one of the preceding claims, wherein the first nucleic acid molecule comprises a sequence of interest of 2 kb or more in length.

### Claim 18

The method of any one of the preceding claims, wherein the first nucleic acid molecule comprises a sequence of interest which is a gene cluster.

### Claim 19 (depends on 18)

The method of claim 18 wherein the gene cluster encodes a secondary metabolite pathway or a fatty acid synthesis pathway.

### Claim 20

The method of any one of the preceding claims wherein the first nucleic acid molecule is a fragment of genomic DNA.

### Claim 21

The method of any one of the preceding claims, wherein the first nucleic acid molecule is a linearised BAC and the method is used to subclone a sequence of interest from the BAC into a cloning vector.

### Claim 22

The method of any one of the preceding claims, wherein the at least first and second nucleic acid molecules are linear and the method further comprises using the product of the linear to linear homologous recombination reaction between the at least first and second nucleic acid molecules in a second step of linear to circular homologous recombination in the presence of Redalpha and Redbeta or truncated RecE and RecT.

### Claim 23 (depends on 22)

The method of claim 22, wherein the linear to linear homologous recombination is carried out in vitro in the presence of full length RecE and RecT, and wherein the method further comprises bringing the product of the linear to linear homologous recombination reaction into contact with a further nucleic acid molecule in a host cell and carrying out linear to circular homologous recombination in vivo in the presence of Redalpha and Redbeta and preferably also Redgamma.

### Claim 24

The method of any one of the previous claims, wherein the first nucleic acid molecule is linear and comprises a phosphorothioation proximal to its 5′ end and a phosphorothioation proximal to its 3′ end.

### Claim 25 (depends on 24)

The method of claim 24, wherein the second nucleic acid molecule is linear and comprises a phosphorothioation proximal to its 3′ end but does not comprise a phosphorothioation proximal to its 5′ end.

### Claim 26

The method of any one of the preceding claims for generating a cDNA library.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A method according to any one of claims 1 to 25, wherein the first and second nucleic acid molecules are linear and wherein the method further comprises bringing the first and second nucleic acid molecules into contact with one or more additional nucleic acid molecules in the presence of the 5′ to 3′ exonuclease and the annealing protein to produce a linear product.

### Claim 28 (depends on 27)

A method according to claim 27, wherein the linear product is a gene, an operon, a chromosome or an entire genome.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6)

A host cell that expresses a 5′ to 3′ exonuclease as described in any one of claims 1 to 6.

### Claim 30 (depends on 29)

The host cell of claim 29, which additionally comprises genes encoding Redalpha and Redbeta, wherein the 5′ to 3′ exonuclease is under the control of a different promoter from Redalpha and Redbeta.

### Claim 31

A host cell comprising a recE gene on an integrated prophage, wherein the recE gene is under the control of a heterologous promoter.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6)

A kit comprising a nucleic acid encoding a 5′ to 3′ exonuclease as recited in any one of claims 1 to 6 for use in a method of homologous recombination.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6)

A kit comprising a 5′ to 3′ exonuclease as recited in any one of claims 1 to 6 for use in a method of homologous recombination

### Claim 34

A method for improving the efficiency of homologous recombination by performing homologous recombination in the presence of at least one single stranded oligonucleotide that has no sequence homology to the nucleic acid molecules undergoing homologous recombination, wherein the efficiency of homologous recombination is improved relative to when homologous recombination is performed in the absence of the at least one single stranded oligonucleotide.

### Claim 35 (depends on 34)

The method of claim 34, wherein the at least one single stranded oligonucleotide comprises or consists of DNA.

### Claim 36 (depends on 34, 35)

The method of claim 34 or 35 wherein the at least one single stranded oligonucleotide is 10-100 nucleotides in length.

### Claim 37 (depends on 36)

The method of claim 36, wherein the at least one single stranded oligonucleotide is about 40 nucleotides in length.

### Claim 38 (depends on 34, 35, 36, 37)

The method of any one of claims 34 to 37, wherein the at least one single stranded oligonucleotide is used at a concentration of 1-200 pmol for each electroporation.

### Claim 39 (depends on 34, 35, 36, 37, 38)

The method of any one of claims 34 to 38, wherein the homologous recombination is mediated by RecE and RecT.

### Claim 40 (depends on 39)

The method of claim 39, wherein the RecE is truncated RecE.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 34, 35, 36, 37, 38, 39)

The method of any one of claims 34-39, wherein the method of homologous recombination is a method according to any one of claims 1 to 28.

### Claim 42 (depends on 34, 35, 36, 37, 38)

The method of any one of claims 34 to 38, wherein the homologous recombination is mediated by Red alpha and Red beta.

### Claim 43 (depends on 34, 35, 36, 37)

A kit comprising at least one single stranded oligonucleotide as recited in any one of claims 34 to 37 for use in performing homologous recombination.

### Claim 44 (depends on 32, 33, 43)

A kit according to any one of claim 32, 33 or 43, wherein the kit comprises a host cell which comprises a nucleic acid encoding a RecE.

### Claim 45 (depends on 24, 25, 26, 44)

A kit according to claim 44, wherein the host cell is a cell as described in any one of claims 24-26.

### Claim 46 (depends on 43)

A kit according to claim 43, wherein the kit comprises a host cell that expresses Redalpha and Redbeta.

### Claim 47 (depends on 44, 45)

A kit according to claim 44 or claim 45, wherein the host cell additionally comprises a nucleic acid sequence encoding one or more of Red gamma, RecA, Redalpha and Redbeta.

### Claim 48 (depends on 32, 33, 43, 44, 45, 46, 47)

A kit according to any one of claims 32, 33 and 43-47, wherein the kit additionally comprises one or more linearised cloning vectors.

### Claim 49

A method for performing homologous recombination between at least a first nucleic acid molecule and a second nucleic acid molecule which share at least one region of sequence homology, comprising, prior to performing homologous recombination in vivo, the step of linearising at least one circular nucleic acid molecule in vivo using a rare-cutting sequence specific DNA cleaving enzyme to generate the first and/or the second nucleic acid molecule.

### Claim 50 (depends on 49)

The method of claim 49, wherein the rare-cutting sequence specific DNA cleaving enzyme is selected from a homing endonuclease, a zinc finger nuclease (ZFN) or transcription activation-like effector nuclease (TALEN).

### Claim 51 (depends on 50)

The method of claim 50, wherein the homing endonuclease is selected from the group consisting of I-SceI, I-CeuI, I-CreI, I-ChuI, I-CsmI, I-DmoI, I-PanI, I-SceII, I-SceIII, I-SceIV, F-SceI, F-SceII, PI-AaeI, PI-ApeI, PICeuI, PI-CirI, PI-CtrI, PI-DraI, PI-MavI, PI-MflI, PI-MgoI, PI-MjaI, PI-MkaI, PI-MleI, PI-MtuI, PI-MtuHI, PI-PabIII, PI-PfuI, PI-PhoI, PI-PkoI, PI-PspI, PI-RmaI, PI-SceI, PI-SspI, PI-TfuI, PI-TfuII, PI-TliI, Pi-TliII. PI-TspI, PI-TspII, PI-BspI, PI-MchI, PI-MfaI, PI-MgaI, PI-MgaII, PI-MinI, PI-MmaI, Pi-MshI, PI-MsmII, PI-MthI, PI-TagI, PI-ThyII, I-NcrI, I-NcrII, I-PanII, I-TevI, I-PpoI, I-DirI, I-HmuI, I-HmuII, I-TevII, I-TevIII, F-SceI, F-SceII (HO), F-SuvI, F-TevI, and F-TevII.

### Claim 52 (depends on 49, 50, 51)

The method of any one of claims 49 to 51, wherein the homologous recombination is mediated by RecE and RecT.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 34, 35, 36, 37, 38, 39, 40, 41, 42, 49, 50, 51, 52)

The method of any one of claims 49 to 52, wherein the method of homologous recombination is a method according to any one of claims 1 to 28 or 34 to 42.

### Claim 54 (depends on 29, 30, 31, 50, 51)

A host cell according to any one of claims 29-31, further comprising a rare-cutting sequence specific DNA cleaving enzyme as recited in claim 50 or claim 51.

### Claim 55 (depends on 50, 51)

A kit for use in performing a method of homologous recombination comprising at least one rare-cutting sequence specific DNA cleaving enzyme as recited in claim 50 or claim 51.

### Claim 56 (depends on 54)

A kit for use in performing a method of homologous recombination comprising a host cell according to claim 54.
